| Autor: |
Xu-Kun Wu, Lan-Fang Yang, Yu-Feng Chen, Zhong-Wu Chen, Hao Lu, Xue-Yi Shen, Min-Hui Chi, Liang Wang, Hui Zhang, Jia-Fei Chen, Jing-Yao Huang, Yong-Yi Zeng, Mao-Lin Yan, Zhi-Bo Zhang |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine, Vol 67, Iss , Pp 102367- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5370 |
| DOI: |
10.1016/j.eclinm.2023.102367 |
| Popis: |
Summary: Background: The synergistic effect of locoregional therapy in combination with systemic therapy as a conversion therapy for unresectable hepatocellular carcinoma (uHCC) is unclear. The purpose of this study was to evaluate the efficacy and safety of transcatheter arterial chemoembolisation (TACE) combined with lenvatinib and camrelizumab (TACE + LEN + CAM) as conversion therapy for uHCC. Methods: This single-arm, multicentre, prospective study was conducted at nine hospitals in China. Patients (aged 18–75 years) diagnosed with uHCC, an Eastern Cooperative Oncology Group performance score (ECOG-PS) of 0–1 and Child-Pugh class A received camrelizumab (200 mg, every 3 weeks) and lenvatinib (bodyweight ≥60 kg: 12 mg/day; |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
